Login
$PLX
$3.03 +$0.00 (0.0%) After hours

$PLX SEC Filings

Filed On Filing
10 Nov 2026 10-Q
10 Nov 2026 8-K: Results of Operations and Financial Condition

Company to host conference call and webcast today at 8:00 a.m. ET

15 Oct 2026 SCHEDULE 13G
09 Sep 2026 Form 4: Schwartz Aharon, Director

Granted 17,000 Stock Options (Right to Buy) · Granted 8,500 Restricted Stock Units

04 Sep 2026 Form 4: Naos Yaron, Sr. VP & COO

Granted 112,000 Stock Option (Right to Buy) · Granted 56,000 Restricted Stock Units

04 Sep 2026 Form 4: Elze Christian, Director

Granted 17,000 Stock Options (Right to Buy) · Granted 8,500 Restricted Stock Units

04 Sep 2026 Form 4: Melincoff Gwen A, Director

Granted 17,000 Stock Options (Right to Buy) · Granted 8,500 Restricted Stock Units

04 Sep 2026 Form 4: Boudes Pol F, Director

Granted 17,000 Stock Options (Right to Buy) · Granted 8,500 Restricted Stock Units

04 Sep 2026 Form 4: Bashan Dror, Director

Granted 320,000 Stock Option (Right to Buy) · Granted 160,000 Restricted Stock Units

04 Sep 2026 Form 4: Bar-Shalev Amos, Director

Granted 17,000 Stock Options (Right to Buy) · Granted 8,500 Restricted Stock Units

04 Sep 2026 Form 4: Ben Zvi Shmuel, Director

Granted 17,000 Stock Options (Right to Buy) · Granted 8,500 Restricted Stock Units

04 Sep 2026 Form 4: Forster Eliot, Director

Granted 17,000 Stock Options (Right to Buy) · Granted 8,500 Restricted Stock Units

12 Aug 2026 FORM S-8
12 Aug 2026 10-Q
12 Aug 2026 8-K: Results of Operations and Financial Condition

Company to host conference call and webcast today at 8:00 a.m. EDT

29 Jul 2026 SCHEDULE 13G
25 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

1.Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’s business.

21 May 2026 8-K: Regulation FD Disclosure

1 PROTALIX BIOTHERAPEUTICS C O R P O R A T E P R E S E N T A T I O N J u n e 2024 PROTALIX BIOTHERAPEUTICS Pioneering solutions to transform the treatment of rare diseases C O R P O R A T E P R E S E N T A T I O N M a y 2026

13 May 2026 10-Q
13 May 2026 8-K: Results of Operations and Financial Condition

Company to host conference call and webcast today at 8:00 a.m. EDT

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support